IL214784A0 - Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity - Google Patents

Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity

Info

Publication number
IL214784A0
IL214784A0 IL214784A IL21478411A IL214784A0 IL 214784 A0 IL214784 A0 IL 214784A0 IL 214784 A IL214784 A IL 214784A IL 21478411 A IL21478411 A IL 21478411A IL 214784 A0 IL214784 A0 IL 214784A0
Authority
IL
Israel
Prior art keywords
sns
treatment
methods
cancer subjects
brca2 activity
Prior art date
Application number
IL214784A
Other languages
English (en)
Original Assignee
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunesis Pharmaceuticals Inc filed Critical Sunesis Pharmaceuticals Inc
Publication of IL214784A0 publication Critical patent/IL214784A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL214784A 2009-02-27 2011-08-22 Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity IL214784A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15644909P 2009-02-27 2009-02-27
US17001309P 2009-04-16 2009-04-16
PCT/US2010/025737 WO2010099526A1 (en) 2009-02-27 2010-03-01 Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity

Publications (1)

Publication Number Publication Date
IL214784A0 true IL214784A0 (en) 2011-11-30

Family

ID=42224275

Family Applications (1)

Application Number Title Priority Date Filing Date
IL214784A IL214784A0 (en) 2009-02-27 2011-08-22 Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity

Country Status (14)

Country Link
US (3) US20120148564A1 (enExample)
EP (2) EP2400959A1 (enExample)
JP (2) JP5936862B2 (enExample)
KR (2) KR20110132400A (enExample)
CN (2) CN104688732A (enExample)
AU (2) AU2010217796B2 (enExample)
CA (1) CA2753261A1 (enExample)
IL (1) IL214784A0 (enExample)
MX (1) MX348412B (enExample)
NZ (1) NZ594829A (enExample)
RU (1) RU2558835C2 (enExample)
SG (2) SG10201400258SA (enExample)
WO (1) WO2010099526A1 (enExample)
ZA (1) ZA201106199B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005222622B2 (en) 2004-03-15 2011-04-07 Dainippon Sumitomo Pharma Co., Ltd. SNS-595 and methods of using the same
AU2008317400B2 (en) 2007-10-22 2014-10-02 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino) -1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3- carboxylic acid in combination therapy
EP3284745A1 (en) 2008-12-31 2018-02-21 Sunesis Pharmaceuticals, Inc. Composition of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
CN104688732A (zh) * 2009-02-27 2015-06-10 逊尼希思制药公司 利用sns-595治疗具有降低的brca2活性的癌症对象的方法
UA110465C2 (en) 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
US8470817B2 (en) 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
WO2023110045A1 (en) 2021-12-15 2023-06-22 Y-Mabs Therapeutics, Inc. Scfv and antibodies with reduced multimerisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024A (en) * 1849-01-09 Cast-iron gar-wheel
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
ATE209645T1 (de) 1994-06-14 2001-12-15 Dainippon Pharmaceutical Co Neue verbindung, verfahren zu ihrer herstellung und antitumormittel
JPH10173986A (ja) 1996-12-16 1998-06-26 Sony Corp 移動体撮影装置
CA2547077C (en) * 2003-12-01 2015-11-03 Kudos Pharmaceuticals Limited Dna damage repair inhibitors for treatment of cancer
AU2005222622B2 (en) 2004-03-15 2011-04-07 Dainippon Sumitomo Pharma Co., Ltd. SNS-595 and methods of using the same
AU2006287149B2 (en) * 2005-09-02 2013-05-23 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
MX2008015775A (es) 2006-06-12 2009-04-17 Sunesis Pharmaceuticals Inc Compuestos y composiciones para tratamiento de cancer.
US7790274B2 (en) 2006-08-02 2010-09-07 High Impact Technology, Llc Layered panel structure including self-bonded thermoformable and non-thermoformable layer materials
EP2155897A2 (en) * 2007-03-30 2010-02-24 Source Precision Medicine, Inc. d/b/a Source MDX. Gene expression profiling for identification, monitoring, and treatment of prostate cancer
CN104688732A (zh) * 2009-02-27 2015-06-10 逊尼希思制药公司 利用sns-595治疗具有降低的brca2活性的癌症对象的方法

Also Published As

Publication number Publication date
AU2010217796B2 (en) 2015-04-30
ZA201106199B (en) 2012-10-31
JP2012523376A (ja) 2012-10-04
RU2558835C2 (ru) 2015-08-10
KR20170046193A (ko) 2017-04-28
AU2010217796A1 (en) 2011-09-15
NZ594829A (en) 2013-09-27
JP2015145396A (ja) 2015-08-13
SG173855A1 (en) 2011-09-29
RU2011139323A (ru) 2013-04-10
KR20110132400A (ko) 2011-12-07
US20170182015A1 (en) 2017-06-29
CN104688732A (zh) 2015-06-10
US20150202189A1 (en) 2015-07-23
CA2753261A1 (en) 2010-09-02
JP5936862B2 (ja) 2016-06-22
SG10201400258SA (en) 2014-05-29
CN102405045A (zh) 2012-04-04
MX2011008994A (es) 2011-09-15
MX348412B (es) 2017-06-12
WO2010099526A1 (en) 2010-09-02
AU2015207901A1 (en) 2015-08-20
US20120148564A1 (en) 2012-06-14
EP3287126A1 (en) 2018-02-28
EP2400959A1 (en) 2012-01-04

Similar Documents

Publication Publication Date Title
IL218575A0 (en) Treatment of cancer
ZA201300218B (en) Treatment of blood cancer
IL215767A0 (en) Methods of treatment for solid tumors
ZA201209484B (en) Skin antiaging treatment
ZA201208821B (en) Methods of treatment of pancreatic cancer
IL219073A (en) A drug combination for cancer treatment
IL258794B (en) Methods and preparations for the diagnosis and treatment of cancer
SG10201508495VA (en) Combination treatment of cancer
IL217777A0 (en) Methods for treatment of pain
GB0922085D0 (en) Cancer diagnosis and treatment
IL214255A0 (en) Methods and compositions for diagnosis and treatment of cancer
EP2461814A4 (en) PROSTATE CANCER TREATMENT
IL213761A0 (en) Novel ortho-aminoamides for the treatment of cancer
IL214133A0 (en) Skin treatment
IL222958A0 (en) Cancer treatment
ZA201106199B (en) Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
IL215037A0 (en) Treatment of pancreatic cancer
EP2593111A4 (en) NEW COMPOUNDS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
EP2575459A4 (en) CANCER TREATMENT WITH WORDMAN ANALOGA
GB0901837D0 (en) Cancer diagnosis and treatment
GB0916686D0 (en) Treatment of cancer
EP2588866A4 (en) DIAGNOSIS AND TREATMENT OF BRAIN TUMORS
GB0921757D0 (en) Treatment of cancer
GB201017354D0 (en) Treatment of cancer
GB0907098D0 (en) Cancer treatment and diagnosis